Cytel Wins Best CRO- Specialist Provider at 2018 Scrip Awards


Cytel has won Best Contract Research Organization( CRO) – Specialist Providers at the 2018 Scrip Awards. The accolade was presented to Cytel at an awards ceremony in London on 28th November 2018. The Scrip Awards acknowledge the pharmaceutical and biotechnology industry’s highest achievers across the value chain. The Best Contract Research Organization – Specialist Providers category highlights the critical role that CROs play in drug development, and particularly commends quality of service and strength of customer relationships. Cytel was selected as the winner by an independent panel of senior industry experts.

Read more

January 2019

Cambridge, MA United States

Cytel Names Joshua Schultz as Chief Executive Officer

  Cytel announced the appointment of Joshua Schultz as Chief Executive Officer (CEO) effective January 7th, 2019. He succeeds Joseph Avellone, who acted as Cytel’s interim CEO from March 2018 and will continue to serve on the company’s Board of Directors.

Mr. Schultz is an accomplished leader with a 20-year track record of success in life sciences and clinical research organizations. He joins Cytel from PAREXEL, where he most recently served as an Officer of the company and Senior Vice President for its Access business unit.  

January 2019

Cambridge, MA United States

Cytel Transforms Biopharmaceutical Go/No-Go Decision-Making with OK GO Software

 Cytel announced the launch of OK GO, the first commercially available software to underpin quantitative go/no-go decision-making frameworks in clinical trials.  The innovative product helps sponsors make faster, more robust decisions about their products to improve their R&D productivity.  OK GO is the commercial release of custom software originally developed as a collaboration between AstraZeneca and Cytel scientists to enhance the established decision-making framework in AstraZeneca’s early clinical development group.

December 2018

Cambridge, MA United States

Cytel Announces Launch of East 6.5

 Cytel Inc., a global provider of advanced analytical solutions to the pharmaceutical, biotechnology, and medical device industries, today announced the launch of East® version 6.5, further enhancing the most trusted technology platform for designing, monitoring, and simulating adaptive trials.  Since 1995, East has empowered trial sponsors of all sizes to optimize study planning and monitoring efforts, accelerate timelines, and increase their probability of success in clinical development.

July 2018

Cambridge, MA United States

News: Announcing EnForeSys 2.0

 Cytel Inc., a global provider of innovative analytical software and services to the biopharmaceutical industry, today announces the release of version 2.0 of its EnForeSys software. The upgraded version unveils expanded functionality that allows users improved interactivity and the ability to generate even more granular forecasts for resolving their feasibility challenges.

March 2018

Cambridge, MA United States

Cytel Announces Launch of East Lite

Cytel announces the launch of its East Lite app on iOS. Developed by the team responsible for East, East Lite features Normal, Binomial, and Survival endpoints and Survival and Non-inferiority designs with options for variance and test statistic.
The free tool is available for download on the App Store and gives biostatisticians the ability to conveniently and quickly create sample size and power calculations using their iPhone or iPad.

February 2018

Cambridge, MA United States

Cytel announced as a finalist in Informa CARE Awards

Cytel is confirmed as a finalist in Most Innovative Trial Design and Clinical Partnership of the Year categories at the Informa Clinical and Research Excellence Awards. The awards recognize innovation and excellence in the biopharma industry and Cytel is commended for its outsourcing partnership with Biogen and a innovative trial design created for sponsor Nestlé Health Science. The winners will be announced in April at an awards ceremony in Boston.

February 2018

Cambridge, MA United States

Cytel congratulates Lipopharma and CLINGLIO on grant award

Congratulations to Lipopharma and the CLINGLIO project consortium on their recent 6,15M€ grant award by the European Union’s Horizon 2020 program. Led by Lipopharma, the multinational consortium brings together 12 academic and industry organizations from Europe, Israel, and the USA.

Cytel collaborated with Lipopharma and the consortium to create the innovative trial design and provided statistical input for the successful grant application.

November 2017

Cambridge, MA United States

Remembering Sarah Fuller

We mourn the loss of Sarah Fuller who passed away on October 29, 2017, at the age of 68. Ms. Fuller served as an instrumental and respected member of Cytel’s board of directors for over 10 years. An influential figure in the pharmaceutical information services sector, Ms. Fuller was the co-founder of Decision Resources Inc., a leading research and advisory firm.  Ms. Fuller also served as Executive Chairman of Millennium Prevention Inc., as a board director of The Forbes Consulting Group, and continued to act as President Emeritus of Decision Resources. Through her work as Chairman and a director, she was also a generous contributor to the work of Cultural Survival, a non-profit organization that promotes the vision, rights and voice of indigenous people. Her varied and impressive career made her an inspiration to many people. 

 Ranganath Nayak, CEO of Cytel; Cyrus Mehta, President and Co-Founder of Cytel; Nitin Patel, Chief Technical Officer and Co-Founder of Cytel; and Per Lofberg, President of Caremark Pharmacy Services share their tributes to Sarah.  To read them click the button below.

October 2017

Cambridge, MA United States

Cytel Adds New Basel Location

Cytel today announced further expansion in Europe with the addition of an office in Basel, Switzerland. The new premises are scheduled to open by the end of 2017 and will join the company’s existing Geneva, Paris, Barcelona, and UK locations in Europe as part of a portfolio of fifteen offices worldwide. 

September 2017

Cambridge, MA United States

Cytel Expands Footprint With New King of Prussia Site

Cytel announced its expansion in the United States with the opening of a new office in King of Prussia, Pennsylvania. The premises will provide significant capacity to further develop Cytel’s established global team, and meet the continued demand for its biometrics-focused clinical research services. 

September 2017

Cambridge, MA United States

Cytel Announced as Scrip Awards Finalist

Cytel is confirmed as finalist in the 2017 Scrip Awards in the category of Best Specialist CRO. The awards recognize innovation and excellence in the biopharma industry and the winners will be announced at a ceremony in London on 29th November. 

May 2017

Cambridge, MA United States

Jim Bolognese named ASA Fellow

James (Jim) Bolognese, Senior Director, Strategic Consulting, Clinical Services at Cytel Inc. was named a 2017 fellow of the American Statistical Association (ASA). Jim will be officially honored by the ASA at the Joint Statistical Meetings in Baltimore, Maryland this summer.

April 2017

Cambridge, MA United States

Cytel wins in Most Innovative Trial Design Category at CARE Awards

In collaboration with client Tracon Pharmaceuticals, Cytel was announced as a winner at the Informa Clinical and Research Excellence Awards for the Most Innovative Trial Design Category. 

March 2017

Cambridge, MA United States

Cytel showcases QPP services at ASCPT

Cytel will showcase its capabilities in this Quantitative Pharmacology and Pharmacometrics space at the American Society for Clinical Pharmacology and Therapeutics (ASCPT) Conference, March 15th – 18th in Washington, DC.

February 2017

Cambridge, MA United States

Cytel announced as finalists at Informa CARE Awards

Cytel is confirmed as a finalist in Most Innovative Trial Design and Best Sponsor-focused Technological Development categories at the Informa Clinical and Research Excellence Awards. The awards recognize innovation and excellence in the biopharma industry and Cytel is recognized for developments on East 6.4 and a innovative trial design created for sponsor Tracon Pharmaceuticals. The winners will be announced in April. 

November 2016

Cambridge, MA United States

Cytel announces successful software implementation at AstraZeneca

Cytel announces the successful implementation of a software interface for go/no-go decision-making within its client AstraZeneca. The software is the result of extensive collaborative work by the two organizations and marks a significant advancement in quantitative decision-making capabilities for the biopharmaceutical industry.

October 2016

Cambridge, MA United States

Cytel expands in Europe and extends big data capabilities

Cytel announces the expansion of its presence in Europe with new offices in Barcelona and Paris. The new sites will enable Cytel to continue to grow its global team of biostatisticians and statistical programmers to support biopharmaceutical customers. The Barcelona location will also serve as a hub for Cytel’s fast-growing data science group. Read the full press release below.

October 2016

Cambridge, MA United States

Mehta and Patel Interview in Chance Magazine

Cytel co-founders Nitin Patel and Cyrus Mehta discuss the history of Cytel in an exclusive interview with Chance magazine.  Find out how it all began and read the article in full via the button below. 

September 2016

Cambridge, MA United States

Cytel selected as Scrip Awards Finalist

Cytel is revealed as one of the 2016 finalists at the Scrip Awards.  The awards celebrate innovation and excellence in the pharmaceutical and biotechnology industry and will take place in London in November. The selection serves as recognition of our team's commitment to innovation and providing solutions for clinical development problems. 

August 2016

Cambridge, MA United States

Cytel co-founder in video discussion with New England Journal of Medicine

Following the publication of their review article Adaptive Designs for Clinical Trials in the New England Journal of Medicine, co-authors Cyrus Mehta and Deepak L. Bhatt were invited to participate in a live video discussion with the journal covering the key features of adaptive trial designs.  To date, the video has received nearly 90,000 views, and may be accessed by clicking the link below. 

June 2016

Cambridge, MA United States

Cytel highlights quality biometrics services at DIA 2016

Cytel highlighted its continued success in delivering high-quality products and outsourcing solutions to the biopharmaceutical industry at the Annual Meeting of the Drug Information Association (DIA) June 26th- 30th 2016 in Philadelphia. Cytel, the world’s largest biometrics CRO and recognized leader in adaptive trial design, supported over 250 clinical research projects in 2015. This includes the addition of further functional partnerships in statistics and statistical programming to its portfolio.

June 2016

Cambridge, MA United States

Release of Data Mining for Business Analytics co-authored by Nitin Patel

The first edition of Data Mining for Business Analytics:  Concepts, Techniques, and Applications with JMP Pro(R) was published in June by Wiley. This book is based on the authors' successful Data Mining for Business Analytics:  Concepts, Techniques, and Applications with XLMiner(R), which first came out in 2006 and is the leading data mining text in the business school and business analyst field. The co-authors are Peter Bruce, Founder and President of the Institute for Statistics Education at, Mia Stephens, Academic Ambassador at the JMP Division of SAS Institute, and Nitin Patel, Chairman and co-Founder of Cytel, Inc


May 2016

Cambridge, MA United States

Cytel launches East 6.4

 Cytel Inc., a global provider of adaptive trial design software, statistical consultancy, and clinical research services, today announced the release of East® version 6.4. East®, the life science industry’s leading clinical trial design platform, will deliver expanded functionality to support the application of groundbreaking methods including multi-arm multi-stage designs, and dual agent dose escalation designs for combination therapies. The innovative designs incorporated in the 6.4 release address key pain points of sponsors and researchers looking to apply advanced statistical strategies with potential to accelerate development.

May 2016

Cambridge, MA United States

Press Release: Cytel congratulates client on Phase 3 data

Cytel Inc., a global provider of clinical research services and software, congratulates its client Flexion Therapeutics, Inc. on the release of Phase 3 data for its lead drug candidate Zilretta (also known as FX006). It was announced in February that the Phase 3 clinical trial met its primary endpoint at week 12, demonstrating highly significant (p<0.0001), durable and clinically meaningful pain relief against placebo in patients with moderate to severe osteoarthritis (OA) knee pain.

Cytel delivered statistical design, analysis and reporting services for the Phase 3 double-blind placebo-controlled, active-comparator trial.

April 2016

Cambridge MA, United States

In the News: Biospace report on Cytel's success

On April 7th 2016, industry publication Biospace reported on our evolution from a niche provider to a global biometrics CRO and leading software company. The article highlights examples of recent work which have led to regulatory approvals for our customers.  With plans for continued expansion, Yannis Jemiai, VP Cytel Consulting, Software Solutions and Marketing commented that "We anticipate growing by about 40 percent this year. It’s a pretty exciting time. We like to focus on and deliver quality."

March 2016

London, United Kingdom

Innovation at 5th East User Group Meeting

The East User Group Meeting successfully brought together trial design and statistics innovators from industry and academia. Participants also gained practical experience with the new functionality of upcoming East 6.4 which was previewed at the event.  View videos of the presentations by clicking below. 

December, 2015

Award presented at
IISA annual meeting

Cyrus Mehta Wins IISA Lifetime Achievement Award

Cytel President and Co-Founder Cyrus Mehta is the 2015 unanimous selection for the IISA Lifetime Achievement Award. Said the IISA: "We are most proud of Dr. Mehta's achievements, we greatly appreciate his exemplary leadership, and are most grateful for his unrelenting support." At the annual meeting, Cyrus presented his latest research: "Inference for Multi-Arm Multi-Stage Adaptive Clinical Trials".

November, 2015

Play video free,
no requirements

EnForeSys® Enrollment Forecasting Predictive Software

Learn how EnForeSys software simulations can accurately predict enrollment patterns.  Chuck Gelb and Charles Liu reveal the value of testing recruitment rate assumptions early to identify potential challenges. They describe how companies use EnForeSys to generate models that dramatically improve feasibility study accuracy rates.

November, 2015

Re-watch presentations,
Download expert slides

Watch: Innovative Design and Optimal Trial Decision-Making

The November 5th Cytel and Sanofi Trial Design Symposium presented ways to implement innovative approaches to dose-finding and escalation trials, ultimately to better support confirmatory efforts.  Watch the presentations from design and decision experts at AstraZeneca, Sanofi, Takeda and Cytel.

2015 Publication

Trial methodology
innovations in practice

Cytel President in Published in Nature Journal

Cyrus Mehta, Cytel president and co-founder, co-authored new paper on emerging Efficacy-to-Effectiveness trials in Nature's Clinical Pharmacology & Therapeutics.  Cyrus is a noted author on the subject of successfully implementing clinical trial methodology innovations.

2014 Case Study

Adaptive trials, Advanced
biometrics combined

Cytel Supports Raptor Pharma’s First Approved Product

Raptor Wall Street

Raptor Pharmaceuticals CMO Patrice Rioux reveals how Cytel’s adaptive trial design and biometrics services played a pivotal role in the fast approval of Raptor's PROCYSBI. Despite issuance of an FDA SPA, the resultant adaptive trial design, medical writing and data handling plan assured their submission was thoroughly primed for approval.

In Memorial

Born: June 21, 1927
Died: November 15, 2014

Professor Marvin Zelen Remembered: Cytel Board Member, Statistical Mentor, Humanitarian

Cytel friends and family continue to find inspiration in the memory of Professor Marvin Zelen. Marvin was an historic biostatistician, inspiring mentor and beloved friend of the Harvard School of Public Health community.  Marvin served on Cytel's Board of Directors from its inception.